Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Vortioxetine (Lu AA21004) in the Prevention of Relapse of Major Depressive Episodes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Major Depressive Episode (MDE) as the primary diagnosis according to DSM-IV TR criteria~* At least one other MDE before the current one~* Moderate to severe depression~Exclusion Criteria:~* Any current psychiatric disorder other than Major Depressive Disorder (MDD) as defined in the DSM-IV TR~* Any substance disorder within the previous 6 months~* Female patients of childbearing potential who are not using effective contraception~* Use of any psychoactive medication 2 weeks prior to screening and during the study~Randomisation Criteria: Patients in remission (MADRS total score \<=10) at both Week 10 and Week 12~Other protocol-defined inclusion and exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Vortioxetine: 5 or 10 mg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).